<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347474</url>
  </required_header>
  <id_info>
    <org_study_id>DBS Methamphetamine</org_study_id>
    <nct_id>NCT03347474</nct_id>
  </id_info>
  <brief_title>Novel Deep Brain Stimulation in Ventral Capsule/Ventral Striatum for Methamphetamine Addiction</brief_title>
  <official_title>Novel Deep Brain Stimulation in Ventral Capsule/Ventral Striatum for Methamphetamine Addiction: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the efficacy of bilateral deep brain
      stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS) as a novel treatment in
      severe methamphetamine addiction. Our hypothesis is that bilateral DBS of the VC/VS will
      significantly reduce the craving for methamphetamine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will receive bilateral surgical implantation of DBS system</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 10-point visual analog scale of carving</measure>
    <time_frame>Baseline (preoperative),3 months,6 months, 12 months</time_frame>
    <description>The score of scale is from 0 to 10. 0 represents no carving for drug, 10 means the greatest degree of carving for drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in Addiction Severity Index(ASI)</measure>
    <time_frame>Baseline（preoperative）,6 months,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Hamilton Anxiety Scale</measure>
    <time_frame>Baseline（preoperative）,3 months, 6 months, 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hamilton Depression Scale</measure>
    <time_frame>Baseline（preoperative）,3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Quality of Life Assessment (SF-36)</measure>
    <time_frame>Baseline（preoperative）,3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in World Health Organization Quality of Life-BREF(WHO-BREF)</measure>
    <time_frame>Baseline（preoperative）,3 months,6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chang in Pittsburgh Sleep Quality Index</measure>
    <time_frame>Baseline（preoperative）,3 months,6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological measures(Scores of cogstate battery)</measure>
    <time_frame>Baseline（preoperative）,6 months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Structured Clinical Interview for DSM-IV Axis II(SCID-II)</measure>
    <time_frame>Baseline（preoperative）,6 months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fagerstrom Test of Nicotine Dependence(FTND)</measure>
    <time_frame>Baseline（preoperative）,3 months,6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Treatment Methamphetamine Addiction</condition>
  <arm_group>
    <arm_group_label>Bilateral surgical implantation of DBS system to VC/ VS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device：Suzhou Sceneray® DBS system</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral surgical implantation of DBS system to VC/ VS</intervention_name>
    <description>The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.</description>
    <arm_group_label>Bilateral surgical implantation of DBS system to VC/ VS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV-TR diagnosis of Drug addiction disorder;

          -  Age 18-65 years old;

          -  Proficiency in Mandarin language;

          -  Failure to detox more than three times;

          -  Capacity to provide informed consent (understanding of the study purpose and methods);

        Exclusion Criteria:

          -  Severe suicidal tendency;

          -  Multidrug abuse and formation of addiction;

          -  Serious and unstable organic diseases (e.g. unstable coronal heart disease);

          -  Any history of seizure disorder or hemorrhagic stroke;

          -  Past stereotactic neurosurgical intervention;

          -  Neurological disease (Abnormal PET-CT, MRI, EEG)

          -  Contraindications of MRI-examination, e.g. implanted cardiac pacemaker/ heart
             defibrillator;

          -  Contraindications of stereotactic intervention, e.g. increased bleeding disposition,
             cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular
             diseases);

          -  HIV positive;

          -  Pregnancy and/or lactation;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chencheng Zhang, MD</last_name>
    <phone>+086-18217122884</phone>
    <email>i@cczhang.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital Functional Neurosurgery</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chencheng Zhang, MD</last_name>
      <phone>+086-18217122884</phone>
      <email>i@cczhang.org</email>
    </contact>
    <contact_backup>
      <last_name>Yingying Zhang, MSc</last_name>
      <phone>+086-17602137369</phone>
      <email>zhyy019@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang C, Li D, Zeljic K, Tan H, Ning Y, Sun B. A Remote and Wireless Deep Brain Stimulation Programming System. Neuromodulation. 2016 Jun;19(4):437-9. doi: 10.1111/ner.12448.</citation>
    <PMID>27321195</PMID>
  </reference>
  <reference>
    <citation>Kuhn J, Möller M, Treppmann JF, Bartsch C, Lenartz D, Gruendler TO, Maarouf M, Brosig A, Barnikol UB, Klosterkötter J, Sturm V. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry. 2014 Feb;19(2):145-6. doi: 10.1038/mp.2012.196. Epub 2013 Jan 22.</citation>
    <PMID>23337942</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Director of the Department of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Bilateral Ventral Capsule/ Ventral Striatum</keyword>
  <keyword>Methamphetamine Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

